-The effects of a monoclonal antibody (B8E5) directed against the second extracellular loop of the muscarinic M2 receptor were studied on the L-type Ca 2ϩ currents (ICa,L) of guinea pig ventricular myocytes using the whole cell patchclamp technique. Similar to carbachol, B8E5 reduced the isoproterenol (ISO)-stimulated ICa,L but did not significantly affect basal ICa,L. Atropine blocked the inhibitory effect of B8E5. The electrophysiological parameters of ISO-stimulated ICa,L were not modified in presence of B8E5. Inhibition of ICa,L by B8E5 was still observed when intracellular cAMP was either enhanced by forskolin or maintained constant by using a hydrolysis-resistant cAMP analog (8-bromoadenosine 3Ј,5Ј-cyclic monophosphate) or by applying the phosphodiesterase inhibitor IBMX. The effect of B8E5 was mimicked by 8-bromoguanosine 3Ј,5Ј-cyclic monophosphate, a potent stimulator of cGMP-dependent protein kinase, and prevented by a selective inhibitor of nitric oxide-sensitive guanylyl cyclase {1H-(1,2,4)oxadiazolo[4,3-a]quinoxaline-1-one}. These results indicate that the antibody B8E5 inhibits the ␤-adrenergic-stimulated ICa,L through activation of the M2 muscarinic receptor and further suggest that the antibody acts not via the classical pathway of decreasing intracellular cAMP, but rather by increasing cGMP. M 2 muscarinic receptor; guanosine 3Ј,5Ј-cyclic monophosphate-dependent protein kinase pathway; autoantibodies; guinea pig ventricular myocytes CIRCULATING AUTOANTIBODIES against G protein-coupled cardiovascular receptors such as ␤-adrenergic and M 2 muscarinic receptors have been demonstrated in patients with idiopathic dilated cardiomyopathy (36, 70), malignant hypertension (15), chronic Chagas' heart disease (3, 4, 10, 24, 57, 58) , and also in mice experimentally infected with Trypanosoma cruzi (43). Functional studies have demonstrated that these autoantibodies are able not only to bind to target receptors in the myocardium, but also to induce receptor-mediated biological responses, as partial agonists (24, 46). In chronic chagasic patients, an association was found between the presence of autoantibodies against muscarinic receptors and cardiac dysfunction, pointing to a pathogenic role of such antibodies in the development of chagasic cardiomyopathy (24, 46) .
M 2 muscarinic receptor; guanosine 3Ј,5Ј-cyclic monophosphate-dependent protein kinase pathway; autoantibodies; guinea pig ventricular myocytes CIRCULATING AUTOANTIBODIES against G protein-coupled cardiovascular receptors such as ␤-adrenergic and M 2 muscarinic receptors have been demonstrated in patients with idiopathic dilated cardiomyopathy (36, 70) , malignant hypertension (15) , chronic Chagas' heart disease (3, 4, 10, 24, 57, 58) , and also in mice experimentally infected with Trypanosoma cruzi (43) . Functional studies have demonstrated that these autoantibodies are able not only to bind to target receptors in the myocardium, but also to induce receptor-mediated biological responses, as partial agonists (24, 46) . In chronic chagasic patients, an association was found between the presence of autoantibodies against muscarinic receptors and cardiac dysfunction, pointing to a pathogenic role of such antibodies in the development of chagasic cardiomyopathy (24, 46) .
It has been reported that the antigenic targets for these autoantibodies are located in the second extracellular loop of ␤-adrenergic and M 2 muscarinic receptors (14, 16, 39) . In a recent study, Elies et al. (11) characterized a monoclonal antibody (B8E5) that recognizes the sequence VRTVE, corresponding to the NH 2 -terminal part of the second extracellular loop of the human M 2 muscarinic receptor. The agonist-like activity of this antibody was demonstrated by its ability to decrease the beating rate of neonatal rat cardiomyocytes in culture (11) .
In the present study, we examined the functional effects of the monoclonal antibody B8E5 on L-type Ca 2ϩ channels after ␤-adrenergic prestimulation. We show that B8E5 inhibits the ␤-adrenergic responsiveness of L-type Ca 2ϩ current (I Ca,L ) via a cGMP-dependent pathway.
METHODS

Isolation of single cells.
All experiments were conducted in accordance with institutional guidelines for the care and use of laboratory animals. Guinea pigs were killed by cervical dislocation. The hearts were quickly excised, and single ventricular myocytes were isolated using collagenase and pronase digestion as described elsewhere (34) . Isolated cells were placed in a 100-l chamber on the stage of an inverted microscope (Nikon Diaphot). The chamber was continuously perfused at a rate of 880 l/min with the standard Tyrode solution containing (in mM) 140 NaCl, 5.4 KCl, 1 MgCl 2, 1.8 CaCl 2, 11 glucose, 0.33 NaH2PO4, and 10 HEPES (pH adjusted to 7.3 with NaOH).
Electrophysiology. Whole cell voltage-clamp experiments were conducted using a patch-clamp amplifier (Axopatch 200A; Axon Instruments). The patch pipettes had resistances of 2-5 M⍀ when filled with the internal solution. After achieving whole cell configuration, capacitance and series resistance were compensated. The series resistance was 10.9 Ϯ 0.4 M⍀ (183 cells) and was compensated by 60-80%. The mean capacitance of the cells was 53.4 Ϯ 1.6 pF (183 cells).
Cells were internally dialyzed with pipette solution, which contained (in mM) 110 CsCl, 30 tetraethylammonium (TEA)-Cl, 5 MgATP, 0.1 GTP, 10 HEPES, and 10 EGTA (pH adjusted to 7.1 with CsOH). To eliminate ion currents other than I Ca,L once whole cell recording was achieved, the bath solution was switched to an extracellular solution (TEA-Cs solution) where Na ϩ were substituted by TEA and K ϩ were replaced by Cs ϩ containing (in mM) 140 TEA-Cl, 6 CsCl, 1 MgCl2, 2 CaCl2, 11 glucose, and 10 HEPES (pH adjusted to 7.3 with TEA-OH).
Experiments were conducted at room temperature (24-26°C). Currents were low-pass filtered at 2 kHz and acquired with an analog-to-digital converter (Digidata 1200; Axon Instruments) and pCLAMP 6.02 software (Axon Instruments), at a sampling rate of 5 kHz. I Ca,L was elicited every 6 s by voltage-clamp steps from a holding potential of Ϫ80 to 0 mV for 500 ms. ICa,L amplitude was determined as the difference between peak inward current and the current at the end of the depolarizing pulse. (48) . The antibody was purified from ascitic fluids by adsorption on Protein A (Hi-Trap Protein A; Pharmacia, Uppsala, Sweden) in PBS (150 mM NaCl, 10 mM phosphate, pH 7.4) and subsequent elution with 0.1 M citrate buffer at pH 3.6. The purity of the antibody was assessed by electrophoresis on SDS polyacrylamide gels and its active concentration defined by surface plasmon resonance in a BIAcore instrument as described by Christensen (8) . The active concentration corresponded to 20-30% of the concentration of antibodies as measured by absorbance at 280 nm.
Statistical analysis. Results are expressed as means Ϯ SE (n ϭ number of cells). Statistical significance was evaluated by the two-tailed Student's t-test or ANOVA. In all cases, P Ͻ 0.05 was considered statistically significant.
RESULTS
Effect of B8E5 on nonstimulated and ISO-stimulated
I Ca . We first tested the effects of B8E5 on basal (nonstimulated) I Ca,L of guinea pig ventricular myocytes. Like it has been reported for ACh, a specific muscarinic agonist, this antibody did not change the amplitude of basal I Ca,L significantly. After 6 min of superfusion with 12 nM B8E5, the mean variation of basal I Ca,L was 0.79 Ϯ 6.03% (8 cells) . Therefore, to study the effect of B8E5 on I Ca,L , guinea pig ventricular myocytes were prestimulated with ISO. At a concentration of 0.1 M, ISO increased the peak amplitude of I Ca,L by 192 Ϯ 29% (7 cells), consistent with the concentrationdependent stimulation of I Ca,L by ISO previously reported for guinea pig cells (65) . The superfusion of the monoclonal antibody in the presence of ISO showed a significant inhibition of ISO-stimulated I Ca,L . B8E5 at 12 nM reduced the ISO-stimulated I Ca,L by 42.8 Ϯ 6.6% (7 cells). A typical time course for the reduction of I Ca,L induced by B8E5 is illustrated in Fig. 1A . The effect of B8E5 on ISO-stimulated I Ca,L reached a steady level in 2-4 min after the onset of superfusion, and it was irreversible under the time limits used for measurement. Figure 1B shows the current traces recorded at the time points denoted by the letters a, b, and c in Fig.  1A . Peak I Ca,L amplitude, normalized relative to cell capacitance (pA/pF) as a function of current-voltage (I-V) relationships, before and after exposure to ISO or ISO plus B8E5 is plotted in Fig. 1C . A comparison of the I-V curves shows that ISO, at 0.1 M, evoked an increase of I Ca,L amplitude at every voltage with respect to the control conditions and, as reported in the literature, shifted the peak I Ca,L to more negative potentials (40) . Figure 1C also shows a decrease of I Ca,L amplitude in presence of ISO with B8E5, relative to ISO-stimulated I Ca,L , but with no significant shift in peak current potential. Figure 1D compares the inhibitory effect of carbachol (CCh), a muscarinic agonist, and B8E5 on the ISO-stimulated I Ca,L . CCh at 1 M reduced the stimulatory effect of ISO on I Ca,L by 26.97 Ϯ 8.07% (n ϭ 6). In nine other experiments, a higher concentration of CCh (10 M) inhibited the ISO-stimulated I Ca,L by 60.62 Ϯ 9.07%. Atropine, a nonspecific muscarinic antagonist, significantly attenuated the inhibitory effects of CCh and B8E5 on ISOstimulated I Ca,L . In the presence of 10 M atropine, 10 M CCh reduced I Ca,L by only 18.6 Ϯ 10.5% (n ϭ 4). Application of 12 nM B8E5, in the presence of 10 M atropine, induced no significant effect on ISO-stimulated I Ca,L . The mean I Ca,L variation was Ϫ3.6 Ϯ 2.0% in seven cells.
Effect of B8E5 on electrophysiological parameters of ISO-stimulated I Ca,L . To investigate the effect of B8E5 on the voltage dependence of the Ca 2ϩ channel, activation and inactivation curves for I Ca,L were determined. The I Ca,L activation curve was constructed from the I-V relationship by dividing I Ca,L by the driving force. The apparent reversal potential of I Ca,L (E Ca ) was estimated by linear regression through the data points in the descending part of the I-V curve where I Ca,L is fully activated (ϩ20 to ϩ40 mV). The amplitude of I Ca,L at each potential was normalized to the predicted maximal current at that voltage estimated from the fully activated I-V relationship. Figure 2A shows the normalized estimated steady-state activation curves in control, 0.1 M ISO, and in presence of both ISO and 12 nM B8E5. The experimental points were fitted to a Boltzmann function to determine the half-activation voltage (V1⁄2) and the slope factor (k). Under control conditions, V1⁄2 was Ϫ11.0 Ϯ 0.5 mV and k was 5.2 Ϯ 0.1 mV (n ϭ 58). In the presence of ISO, V1⁄2 was Ϫ26.7 Ϯ 2.9 mV and k was 4.5 Ϯ 0.2 mV (n ϭ 15). Under both ISO and B8E5, V1⁄2 was Ϫ28.0 Ϯ 1.1 mV and k was 4.8 Ϯ 0.3 mV (n ϭ 14). Thus ISO induces a modification of the voltage dependence of activation of the Ca 2ϩ channel characterized by a negative shift with no change in the slope as previously described (40) . When B8E5 was superfused together with ISO, no statistical difference was observed either in V 1 ⁄2 or k. Similar results were obtained when we looked at the steadystate inactivation curves, obtained by using the classical double-pulse protocol for a voltage range of Ϫ80 to ϩ40 mV from a holding potential of Ϫ80 mV and test pulse of 0 mV. The results were fitted, at the interval from Ϫ50 to 0 mV, with a Boltzmann function to determine the parameters of steady-state inactivation. The inactivation plots in control, 0.1 M ISO, and with 12 nM B8E5 are shown in Fig. 2B . Under control conditions, V1 ⁄2 was Ϫ30.3 Ϯ 0.8 mV and k was 4.8 Ϯ 0.1 mV (n ϭ 38). In the presence of ISO, V1⁄2 was Ϫ38.8 Ϯ 1.3 mV and k was 5.9 Ϯ 0.2 mV (n ϭ 17). When B8E5 was superfused in the presence of ISO, V1⁄2 was Ϫ40.2 Ϯ 0.7 mV with a k of 5.8 Ϯ 0.36 mV (n ϭ 14). The results are comparable with those obtained for the activation curve, a negative shift for the half-inactivation voltage without change in the slope between the control condition and in the presence of ISO, whereas the presence of the antibody induces no statistical difference in the two parameters compared with ISO alone.
Another possible source of I Ca,L decrease by antibody action could be a modification of the time constant for recovery from inactivation of Ca 2ϩ channels, such that even if depolarizing pulses were applied every 6 s, a slowing of the recovery process could induce a decrease in I Ca,L amplitude. To test this possibility, the time course of recovery from inactivation was determined at a holding potential of Ϫ80 mV under the different experimental conditions. The recovery from inactivation could be fitted by a single exponential, with a time constant () in control conditions of 101.7 Ϯ 6.7 ms (n ϭ 18). Figure 2C shows a significant slowing of the time of recovery in the presence of 0.1 M ISO ( ϭ 159.4 Ϯ 12.0 ms, n ϭ 12), but no difference was detected by adding 12 nM B8E5 ( ϭ 162.3 Ϯ 16.4 ms, n ϭ 13). In any case, recovery was complete in ϳ2 s.
Participation of the cAMP-dependent pathway in the effect of B8E5. It is known that ISO increases I Ca,L via a phosphorylation mechanism involving the ␤-adrenergic receptor and a cAMP-dependent pathway and that this effect can be antagonized by the activation of the M 2 muscarinic receptor. The mechanism for this muscarinic inhibition is based on the reduction of intracellular cAMP concentration by a number of distinct reactions (32) . Our aim was to evaluate whether the reduction of I Ca,L induced by the antibody is mediated by cAMP reduction. Furthermore we investigated which of the two principal mechanisms known to reduce cAMP, either the inhibition of adenylyl cyclase via the stimulation of G i protein or the stimulation of cGMP-dependent phosphodiesterase (PDE), was being activated.
Forskolin is a potent activator of adenylyl cyclase (29) . Superfusing the cells with 10 M forskolin increased the amplitude of I Ca,L by 185.6 Ϯ 39.9% (n ϭ 6), as illustrated in Fig. 3A . In accordance with the results observed in the presence of ISO, inhibition of this effect was obtained by the addition of B8E5. In six cells tested, 12 nM B8E5 reduced the forskolin-activated I Ca,L by 25.6 Ϯ 6.3% (Fig. 3D) .
The participation of a PDE in I Ca,L inhibition by B8E5 was excluded when, in the presence of the nonspecific PDE inhibitor IBMX (61), it was still possible to decrease the I Ca,L amplitude with B8E5. IBMX (10 M) increased I Ca,L by 142.9 Ϯ 24.7% (n ϭ 5). In four myocytes, the percent inhibition of IBMX-stimulated I Ca,L by B8E5 was 43.2 Ϯ 5.7% (Fig. 3, B and D) . These data suggest that I Ca,L amplitude reduction by B8E5 is mediated not by a reduction of cAMP levels, but by another mechanism. To reinforce this hypothesis we used 8-BrcAMP, a cAMP analog more resistant to hydrolysis by PDEs than cAMP (49). The external application or internal dialysis of 10 M 8-BrcAMP led to an increase in I Ca,L that was reversed by the application of 12 nM B8E5 (38.4 Ϯ 6.9%, n ϭ 4; Fig. 3, C and D) .
Participation of the cGMP-dependent pathway in the effect of B8E5. Because the previous results suggest that the cAMP pathway does not participate in the reduction of I Ca,L by B8E5, an alternative mechanism was tested. It was shown that muscarinic stimulation would increase cGMP levels in cardiac myocytes (29, 51) . Indeed, in guinea pig ventricular myocytes, cGMP inhibits cAMP-activated I Ca,L , but the mechanism seems to be independent of cGMP-stimulated PDEs (35) . Therefore, we decided to investigate the participation of a cGMP-dependent protein kinase (cGMP-PK)-mediated pathway, by using 8-BrcGMP, a potent membrane-permeable stimulator of cGMP-PK (9). As shown in Fig. 4A , superfusion of 100 M 8-BrcGMP in the presence of 0.1 M ISO significantly reduced the peak amplitude of ISO-stimulated I Ca,L . In four cells, 0.1 M ISO increased I Ca,L by 130.7 Ϯ 15.6%, whereas the addition of 100 M 8-BrcGMP in the presence of ISO decreased I Ca,L by 42.33 Ϯ 5.5%. The finding that 8-BrcGMP reduces ISO-stimulated I Ca,L , in a manner similar to B8E5, lends support to the view that B8E5 may be acting through a muscarinic receptor-mediated elevation of cGMP levels. To further test this hypothesis, we used ODQ, a selective inhibitor of nitric oxide (NO)-sensitive guanylyl cyclase (5, 23) . The superfusion of 10 M ODQ in the presence of B8E5 and ISO after the prestimulation of I Ca,L by 0.1 M ISO blocked the inhibitory effect of B8E5. At steady state, the peak reduction of ISO-stimulated I Ca,L was 5.6 Ϯ 5.9% (n ϭ 6). A typical experiment is shown in Fig. 4B .
DISCUSSION
The present study demonstrates that a monoclonal antibody raised against the second extracellular loop of the muscarinic receptor can decrease the ␤-adrenergic responsiveness of I Ca,L in guinea pig ventricular myocytes by acting as an allosteric agonist through activation of the muscarinic receptor. We also show that the decrease of I Ca,L through the M 2 muscarinic receptor does not pass by the classical cAMP-dependent pathway and that an additional cAMP-independent mechanism exists to reverse the increase in I Ca,L amplitude induced by ␤-adrenergic stimulation. From our results and other reports (25, 59) , it is reasonable to assume a participation of cGMP in the I Ca,L reduction evoked by anti-M 2 receptor antibodies.
The effect passes through the M 2 muscarinic receptor. The immunochemical and pharmacological properties of anti-M 2 muscarinic receptor antibodies found in idiopathic dilated cardiomyopathy (17) or Chagas' disease (10, 25) can be mimicked by the polyclonal rabbit antibodies directed against the second extracellular loop of the target receptor (20) . Moreover, these antibodies have a functional muscarinic activity, as shown by the induction of a negative inotropism and/or chronotropism in vivo (71) as well as in vitro on rat myocytes (18, 19) or rat papillary muscle (54) . Polyclonal antibodies are, however, poor tools to unravel activating mechanisms because polyclonality can induce pleiotropy of response. The availability of a monoclonal anti-M 2 muscarinic receptor antibody with agonist-like effects on neonatal rat cardiomyocytes in vitro (11) makes these mechanistic studies possible. Indeed, this monoclonal antibody (B8E5) was shown to exert its effect only through its target receptor (11) . We confirmed this result by complete inhibition of the effects of B8E5 with the muscarinic antagonist atropine.
How is I Ca, L decreased? The M 2 receptor is the predominant subtype of muscarinic receptors present in the heart of mammalian species (6, 7, 12) . Additionally, some species could coexpress the M 1 receptor (21, 52) . Activation of M 2 and M 4 receptor couples via a pertussis toxin-sensitive G protein (G i /G o ) to inhibition of adenylyl cyclase and inhibits increases in intracellular cAMP, which leads to a reduction in the previously enhanced I Ca,L . M 1 , M 3 , and M 5 receptors couple preferentially via G q/11 to phospholipase C, with subsequent formation of inositol phosphates and diacylglycerol (for recent reviews, see Refs. 6, 7, 12) . It is largely accepted that the M 2 muscarinic inhibitory effect on I Ca,L occurs through the inhibition of adenylyl cyclase, in particular through the activation of G i protein (29, 37) . The decrease of adenylyl cyclase activity leads to a reduction of cAMP production and protein kinase A (PKA) activity. In the present study, this process does not seem to mediate the decrease of I Ca,L amplitude evoked by the antibodies. The reduction was still observed when the level of cAMP was sustained using a nonhydrolyzable cAMP analog. Inhibition of I Ca,L by ACh without changes in cAMP levels or PKA activity has been previously reported (for review, see Ref. 41) . ACh can activate the production of cGMP (29) , and it has been demonstrated that, in cardiac cells, ACh can, via activation of NO synthase (NOS), increase the cGMP level (for review see Ref. 55) . Interestingly, the autoantibodies against M 2 receptors, present in sera of patients with Chagas' disease, also seem to act by the NO signaling pathway (59) . However, some reports have shown that ACh could increase cGMP without increasing NO (22) and also in the presence of NOS inhibitors (45, 56) . Studies on NOS-3 knockout mice were inconclusive, since contradictory findings on the ACh receptor-mediated I Ca,L modulation were observed (28, 67) . Recently, however, it was shown that NO could exert a negative effect on I Ca,L by a cGMP pathway (1). Other reports also indicate an obligatory participation of NO production in the signal transduction cascade involved in the M 2 muscarinic acetylcholine receptor-mediated inhibitory responses of the heart (2, 13, 27) .
In amphibian cells, cGMP activates a cGMP-stimulated PDE that hydrolyzes cAMP and thereby decreases I Ca,L (30) . But even if the anti-M 2 muscarinic receptor antibodies from chagasic patients have been reported to increase cGMP levels via NO (59, 60) , the participation of PDEs in the inhibition observed here is excluded for two reasons. First, the preponderant PDE in guinea pig ventricular cardiomyocytes is the cGMPinhibited PDE (PDE3), so cGMP production would induce an increase of cAMP and consequently an enhancement of I Ca,L amplitude (47, 53) . Second, the decrease of I Ca,L by B8E5 was observed in the presence of a nonselective PDE inhibitor (IBMX), which suggests the presence of another target for the action of cGMP. An alternative mechanism that could be proposed is the decrease of I Ca,L via activation of cGMP-PK. Levi et al. (35) were the first to describe the participation of cGMP-PK, in guinea pig cardiomyocytes. These results have been confirmed in guinea pig (44, 47, 53, 68) , rat (42, 62) , chick (26, 64) , and rabbit cardiac cells (63) . This hypothesis is supported by the observations that a potent stimulator of cGMP-PK, the cGMP-analog 8-BrcGMP, mimicked the effect of B8E5 on ISO-stimulated I Ca,L and that the selective inhibitor of NO-sensitive guanylyl cyclase (ODQ) prevents the B8E5 decrease of I Ca,L .
Why do the antibodies seem to activate only the cGMP pathway and not the G i pathway? This could be due to the different active conformations induced with B8E5 compared with a normal muscarinic agonist, CCh. Indeed, the antibody B8E5 acts by functional dimerization of the muscarinic receptor, since monovalent Fab fragments of this antibody lack a negative chronotropic effect, but their activity can be restored after cross-linking of the fragments with an anti-mouse IgG (11) . Functional dimerization of the receptors has already been postulated for the muscarinic receptor by Maggio et al. (38) and for ␤2-adrenergic receptor by Hebert et al. (31) and is actually proposed as an important functional property of G protein-coupled receptors (50) . Supposing the multiple activating states of G protein-coupled receptors, postulated by Kenakin (33) , the monoclonal antibody could induce an active dimeric conformation leading to G q activation but not G i/o activation. This hypothesis seems to contradict the results of Valenzuela et al. (66) , who have shown that the accentuated antagonism induced by CCh was absent in G o ␣ knockout mouse ventricular myocyte, indicating an obligate participation of G o for the muscarinic regulation of I Ca,L . In fact, our results confirm that the antibody does not act as full agonist-like ACh or CCh but induces a specific dimeric conformation that could associate with G q protein, although other transduction mechanisms cannot be excluded. This is also confirmed by the fact that, in contrast to CCh, the antibodies do not lead to desensitization of the receptor (69) .
Clinical implications. Autoantibodies against M 2 receptors are associated with some of the pathological symptoms present in cardiomyopathies such as chronic Chagas' disease (24, 25, 46) . Although targeted to different epitopes at the second extracellular loop of the M 2 receptor, these antibodies share with the monoclonal antibody the agonist-like activity and seem to act by inducing a dimeric conformation that allows the activation of an alternate transduction pathway, which is probably mediated by G q . This could lead to potentially deleterious consequences for heart function, as has been shown in rabbits that were immunized with a peptide encompassing the epitope recognized by the monoclonal antibody (19) . Therefore, the monoclonal antibody B8E5 could be of value in further studies of molecular mechanisms of receptor activation by such autoantibodies and could point to potential therapeutic interventions that could eliminate antibody-induced pathological symptoms.
